Lean nonalcoholic fatty liver disease and sarcopenia

Front Endocrinol (Lausanne). 2023 Jun 23:14:1217249. doi: 10.3389/fendo.2023.1217249. eCollection 2023.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world. The risk factor for NAFLD is often considered to be obesity, but it can also occur in people with lean type, which is defined as lean NAFLD. Lean NAFLD is commonly associated with sarcopenia, a progressive loss of muscle quantity and quality. The pathological features of lean NAFLD such as visceral obesity, insulin resistance, and metabolic inflammation are inducers of sarcopenia, whereas loss of muscle mass and function further exacerbates ectopic fat accumulation and lean NAFLD. Therefore, we discussed the association of sarcopenia and lean NAFLD, summarized the underlying pathological mechanisms, and proposed potential strategies to reduce the risks of lean NAFLD and sarcopenia in this review.

Keywords: insulin resistance; lean non-alcoholic fatty liver disease; metabolic inflammation; sarcopenia; visceral obesity.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Insulin Resistance*
  • Non-alcoholic Fatty Liver Disease* / pathology
  • Obesity / complications
  • Risk Factors
  • Sarcopenia* / complications

Grants and funding

This work was supported by Youth Science Discipline Leading Project of Shanghai Municipal Health Commission (No.2022XD023).